ESC 2019

ESC 2019 | DAPA-HF: Dapagliflozin Shows Benefit for All Subgroups

Dapagliflozin (a sodium glucose co-transporter 2 inhibitor), when indicated concomitantly with standard therapy, reduces significantly the...

ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes”

In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the...

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease

For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization...

ESC 2019 | CONDI-2ERIC-PPCI: Final Blow Against Ischemic Pre-Conditioning in Primary Angioplasty

Remote ischemic conditioning does not offer any clinical benefit to patients with ST-segment elevation acute myocardial infarction...

ESC 2019 | ISAR-REACT 5 | Which Is Better in ACS, Prasugrel or Ticagrelor?

Courtesy of Dr. Carlos Fava. The benefit of dual antiplatelet therapy in acute coronary syndromes (ACS) has been...

ESC 2019

Here you will find the highlights of the ESC 2019 Congres, held on August 31st to September...

ESC 2019 | PARAGON-HF: Sacubitril/Valsartan Somewhat Disappointing, though a Few Would Benefit.

The combination Sacubitril/valsartan did not reduce the risk of rehospitalization for heart failure or cardiovascular death in...

ESC 2019 | THEMIS-PCI: Unlike in the Main Study, Here Ticagrelor Is Indeed Effective

This is a sub-study of the THEMIS presented during the ESC 2019 scientific sessions in Paris, and...